Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial-Reference-Cited by-同舟云学术

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Published:2021-09 Issue:9 Volume:22 Page:1250-1264
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Bono Johann S,Mehra Niven,Scagliotti Giorgio V,Castro Elena,Dorff Tanya,Stirling Adam,Stenzl Arnulf,Fleming Mark T,Higano Celestia S,Saad Fred,Buttigliero Consuelo,van Oort Inge M,Laird A Douglas,Mata Marielena,Chen Hsiang-Chun,Healy Cynthia G,Czibere Akos,Fizazi Karim

Funder

Pfizer Ltd

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. PARP inhibitors: synthetic lethality in the clinic;Lord;Science,2017

2. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors;Chung;JCO Precis Oncol,2019

3. The long tail of oncogenic drivers in prostate cancer;Armenia;Nat Genet,2018

4. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer;Castro;J Clin Oncol,2019

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talazoparib for the treatment of prostate cancer;Expert Opinion on Pharmacotherapy;2024-08-29

2. Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review;Current Medical Research and Opinion;2024-08-27

3. Detection and analysis of the safety profile of talazoparib based on FAERS database;Expert Opinion on Drug Safety;2024-08-17

4. Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies;Cancers;2024-08-06

5. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer;Drugs;2024-07-26